Alaunos Therapeutics, Inc. (TCRT) income statement
TCRTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 4/30
$1.66+0.07 (+4.40%)
Close on Nov 20, 2026Market cap $4.22MP/E –Yield –
Alaunos Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -135266.7%
- Net margin
- -133666.7%
- Return on equity, FY2025
- -198.1%
Financial strength
- Current ratio
- 0.77
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 14.4%
Valuation
- P/E ratio
- –
- Price to sales
- 1405.73
- Price to book
- 6.47
- Dividend yield
- –
See a number that looks wrong?